| Deal value | $1.7B |
|---|---|
| Share of market cap | 648.3% |
Key highlights
- Standalone closing valuation set at $1.71 billion for Power Analytics Global Corp
- Original $2.85 billion valuation included APQC Inc and UltraSolar intellectual property
- Merger consideration to be paid entirely in DMAA shares with no earnout provisions
- Reversion event triggered if APQC acquisition fails to close by November 1, 2026
- Outside closing date for the business combination is set for April 29, 2027
What Is the Deal?
Drugs Made In America Acquisition Corp. (DMAA) has entered into an amendment to its existing merger agreement with Power Analytics Global Corp (PAGC). The primary change establishes a dual-valuation structure based on the completion of third-party acquisitions by the target. If PAGC fails to acquire APQC Inc and the UltraSolar intellectual property by November 1, 2026, the transaction will proceed at a standalone valuation of $1.71 billion. This is a reduction from the initial $2.85 billion enterprise value that assumed the inclusion of those specific assets. The merger is expected to close by the outside date of April 29, 2027.
Up 0.3% since our story on 21 Oct: $10.87 when we broke it → $10.90 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $10.87 |
|---|---|
| 20 Oct | $10.87 |
| 21 Oct | $10.87 |
| 22 Oct | $10.88 |
| 23 Oct | $10.88 |
| 26 Oct | $10.88 |
| 27 Oct | $10.87 |
| 28 Oct | $10.87 |
| 29 Oct | $10.88 |
| 30 Oct | $10.89 |
| 2 Nov | $10.88 |
| 3 Nov | $10.88 |
| 4 Nov | $10.88 |
| 5 Nov | $10.89 |
| 6 Nov | $10.89 |
| 9 Nov | $10.89 |
| 10 Nov | $10.90 |
| 11 Nov | $10.90 |
| 12 Nov | $10.90 |
| 13 Nov | $10.90 |
| 16 Nov | $10.90 |
Deal Structure & Terms
- Merger consideration is payable entirely in newly issued ordinary shares of DMAA at the designated Reference Price.
- The agreement contains no earnout or contingent consideration provisions following the closing.
- Standalone valuation excludes UltraSolar and PolariQon intellectual property not owned as of October 13, 2026.
- A Reversion Event occurs if the APQC definitive agreement is terminated or if independent directors deem it unfeasible.
- Any subsequent addition of APQC assets after a Reversion Event requires a supplemental fairness opinion and independent director approval.
Business Overview
Drugs Made In America Acquisition Corp. operates as a special purpose acquisition company (SPAC) based in New York. As a blank check company with no commercial operations, it reported a backlog of zero as of June 30, 2026. The target company, Power Analytics Global Corp, specializes in energy management software and predictive power modeling. The standalone entity encompasses PAGC's existing business operations and intellectual property. The proposed merger aims to transition PAGC into the public markets via DMAA's NASDAQ listing, utilizing the SPAC's structure to provide the necessary capital for continued expansion in the energy technology sector.
Industry Landscape
The energy technology and power analytics sector is seeing increased activity as industrial and commercial entities seek sophisticated tools for grid management and power reliability. Within the broader financial services sector, SPAC-led combinations remain a common route for specialized technology firms to access public capital. DMAA currently trades at a price-to-earnings ratio of 60.36x, with its shares maintaining a stable range near $10.87. The $1.71 billion standalone valuation for PAGC reflects the current market dynamics for energy-related intellectual property, even as the company moves forward without the immediate inclusion of the larger APQC asset portfolio.
| Share price | $10.87 |
|---|---|
| Market cap | $264M |
| P/E (TTM) | 60.4× |
| 1-month price change | +0.14% |
| Sector | Financial ServicesShell Companies |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Drugs Made In America Acquisition Corp. announcing an amendment to its merger agreement with Power Analytics Global Corp.
Track Drugs Made In America Acquisition Corp. live
Get the next Drugs Made In America Acquisition Corp. SEC filing seconds after it lands.



